EMA updates Spinraza's product summary, gives Biogen hope in Denmark
The EMA has added real-world clinical findings for adult patients to the summary for Biogen’s spinal muscular atrophy (SMA) treatment, Spinraza. The company’s Danish division now hopes this will pave the way to expand the drug’s indication in Demark, whose health authority has proved a roadblock many times.
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen
The European Medicines Agency (EMA) has recently updated the product summary for Biogen’s spinal muscular atrophy (SMA) treatment, Spinraza (nusinersen), which now includes real-world clinical data that demonstrates the drug’s effectiveness in stabilizing or improving the motor function of some adults with SMA.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
